Analyses by ER/PR status were not included in the recent UK Biobank study [3], and in the WCRF meta-analysis [1] analyses by hormone receptor status were limited to the more common outcome of postmenopausal breast cancer (ER +/PR+ , 6 studies and 5117 cases; ER−/PR−, 5 studies 1236 cases; restricted to prospective studies). The gene discussed is NR4A1; the disease is breast carcinoma.